National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 12 formulations under the Drugs (Prices Control) Order, 2013, the decision has taken on the basis of the 87th Authority meeting held on dated 27.05.2021. In the NPPA list June 2021 there are a total of 12 formulations that were requested by 12 different manufacturing companies including Abbott Healthcare Limited, Windlass Biotech Pvt. Limited, Hetero Labs Ltd., Cipla Limited, and 8 more.
In June 2021, NPPA issued two lists of ceiling price fixation of different formulations. The first list contains 12 formulations published on June 1, 2021, and the second list contains 3 formulations that are published on June 1, 2021.
Table of Contents
1. DPCO/ NPPA list June 2021
| SL.NO. | NAME OF THE FORMULATION / BRAND NAME | STRENGTH | UNIT | MANUFACTURER & MARKETING COMPANY | RETAIL PRICE(RS.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | Ivabradine Hydrochloride+ Metoprolol TartrateTablet | Each film coated tablet contains: Ivabradine Hydrochloride eq. to Ivabradine 5 mg + Metoprolol Tartrate IP 25 mg | 1 Tablet | M/s Archimedis Healthcare Pvt. Ltd./ M/s Lupin Limited | 15.75 |
| 2 | Ivabradine Hydrochloride+ Metoprolol TartrateTablet | Each film-coated tablet contains: Ivabradine Hydrochloride eq. to Ivabradine 5 mg + Metoprolol Tartrate IP 50 mg | 1 Tablet | M/s Archimedis Healthcare Pvt. Ltd./ M/s Lupin Limited | 18.14 |
| 3 | Telmisartan, Cilnidipine& Metoprolol (ER) Tablet | Each film coated tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg Metoprolol Succinate IP 23.75mg eq. to Metoprolol Tartrate (as extended-release) 25mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Neomac Pharmaceuticals Pvt. Ltd. | 10.16 |
| 4 | Telmisartan, Cilnidipine & Metoprolol (ER) Tablet | Each film coated tablet contains: Telmisartan IP 40mg, Cilnidipine IP 10mg Metoprolol Succinate IP 47.50mg eq. to Metoprolol Tartrate (as extended-release) 50mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd./ M/s Neomac Pharmaceuticals Pvt. Ltd. | 12.41 |
| 5 | Doxycycline & Lactic Acid Bacillus Capsule | Each hard gelatine capsule contains: Doxycycline Hyclate IP eq. to Doxycycline (as pellets) 100mg Lactic Acid Bacillus (As enteric coated pellets) 5 Billion Spores | 1Capsule | M/s Skymap Pharmaceuticals Pvt. Ltd. | 6.94 |
| 6 | Doxycycline & LacticAcid Bacillus Capsule | Each hard gelatin capsule contains Doxycycline Hyclate IP eq. to Doxycycline (as pellets) 100mgLactic Acid Bacillus (As enteric coated pellets) 5 Billion Spores | 1Capsule | M/s SkymapPharmaceuticals Pvt. Ltd. / M/s Glensmith Labs Pvt. Ltd. | 6.94 |
| 7 | Darunavir + Ritonavir Tablet | Each film-coated tablet contains Darunavir Ethanolate eq. Darunavir IP 600mg Ritonavir IP 100mg | 1 Tablet | M/s Hetero Labs Ltd./ M/ Cipla Limited | 145.7 |
| 8 | Povidone-Iodine gargle0.5% w/v | Contains: Povidone Iodine IP 0.5% w/v (availableIodine 0.05% w/v) | 1 ML | M/s Stedman Pharmaceuticals Pvt. Ltd. | 0.66 |
| 9 | Teneligliptin + Metformin Hydrochloride IP (SR) Tablet | Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mgMetformin HydrochlorideIP (As Sustained Release) IP 500mg | 1 Tablet | M/s Windlas Biotech Pvt. Limited / M/s Abbott Healthcare Limited | 11 |
| 10 | Teneligliptin + Metormin HCL (ER) Tablet | Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin hydrochloride (As Extended-Release) IP 500mg | 1 Tablet | M/s Morepen Laboratories Limited | 10.96 |
| 11 | Teneligliptin + Metormin HCL (ER) Tablet | Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin hydrochloride (As Extended-Release) IP 1000mg | 1 Tablet | M/s Morepen Laboratories Limited | 11.48 |
| 12 | Teneligliptin + Metformin Hydrochloride IP (SR) Tablet | Each uncoated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate eq. to Teneligliptin 20mg Metformin Hydrochloride IP (As Sustained Release) IP 1000mg | 1 Tablet | M/s Windlas Biotech Pvt. Limited / M/s Abbott Healthcare Limited | 11.48 |
ALSO READ: Latest DPCO List 2021|Current NPPA list 2021
NPPA has fixed retail prices of 3 more formulations under the Drugs (Prices Control) Order, 2013 based on the decision of the 87th Authority meeting held on dated 25.05.2021. Earlier on June 1, 2021, NPPA also fixed 12 formulation prices.
2. DPCO/ NPPA list June 2021.
| SL.NO. | NAME OF THEFORMULATION / BRANDNAME | STRENGTH | UNIT | MANUFACTURER &MARKETINGCOMPANY | RETAILPRICE(RS.) |
| (1) | (2) | (3) | (4) | (5) | (6) |
| 1 | IvabradineHydrochloride + Metoprolol TartrateTablet | Each film coated tablet contains: Ivabradine Hydrochloride eq. toIvabradine 7.5 mg + MetoprololTartrate 25 mg | 1 Tablet | M/s Archimedis Healthcare Pvt. Ltd. / M/s Lupin Limited | 20.68 |
| 2 | Darunavir + RitonavirTablet | Each film coated tablet contains: Darunavir Ethanolate eq.Darunavir IP 800mgRitonavir IP 100mg | 1 Tablet | M/s Hetero Labs Ltd./ M/ Cipla limited | 190.44 |
| 3 | Trastuzumab Concentrate for solution for Infusion in vials | Each vial contains: Trastuzumab 150 mg | Each vial | M/s Roche Products (India) Pvt. Ltd/ M/s Cipla Ltd | 15526.97 |
Important Notes by NPPA for these orders:
(a) The manufacturer of the above-mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the
The government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller
and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display a price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned
above i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under
DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt.
under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e.
the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing
companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be
liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO,
2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
Reference:
- National Pharmaceutical Pricing Authority Official Website.
The author has 18 years of experience in the Quality Control, and Quality Assurance departments of Pharmaceutical Manufacturing Companies. Have exposure of all documents for WHO-GMP audits, Export documents, US-FDA documents, Validation of Pharma machinery, and Quality Control Instruments.
Email: darshansinghknl10@gmail.com